A. Piché

S. Trottier, C. Tremblay, D. Rouleau, 2007, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail.

C. Rancourt, A. Piché, I. Matte, 2015, International journal of oncology.

Resolution of a polyomavirus-mouse hybrid replicon: viral function required for recombination

A. Piché, P. Bourgaux, 1987 .

Resolution of a Polyomavirus-Mouse Hybrid Replicon: Viral Function Required for Recombination

A. Piché, P. Bourgaux, 1987, Journal of virology.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

Chronic Bronchitis: Clearing the Cough

A. Piché, 2005 .

Tumor-mesenchymal stem cell interactions: therapeutic implications for epithelial ovarian cancer

A. Piché, 2018, Translational Cancer Research.

Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

C. Rancourt, A. Piché, D. Lane, 2011, BMC Cancer.

Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.

C. Rancourt, A. Piché, D. Lane, 2003, Cytotherapy.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

C. Rancourt, A. Piché, D. Lane, 2016, Molecular Cancer.

Resolution of a polyomavirus-mouse hybrid replicon: release of genomic viral DNA

A. Piché, P. Bourgaux, 1987, Journal of virology.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

C. Le Page, A. Mes-Masson, D. Huntsman, 2013, Biopreservation and biobanking.

Phenotypic knock-out of the latent membrane protein 1 of Epstein–Barr virus by an intracellular single-chain antibody

T. Curiel, K. Kasono, D. Curiel, 1998, Gene Therapy.

Cell detachment modulates TRAIL resistance in ovarian cancer cells by downregulating the phosphatidylinositol 3‐ kinase/Akt pathway

C. Rancourt, A. Piché, D. Lane, 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

SARS-CoV-2 infection outcomes associated with the Delta variant: A prospective cohort study.

A. Piché, S. Lemaire-Paquette, C. Rioux-Perreault, 2022, Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada.

Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562

M. Hagiwara, K. Kasono, D. Curiel, 2000, Cancer Gene Therapy.

Prevalence of persistent symptoms at least 1 month after SARS-CoV-2 Omicron infection in adults.

Bcl-2 decreases cell proliferation and promotes accumulation of cells in S phase without affecting the rate of apoptosis in human ovarian carcinoma cells.

C. Rancourt, A. Piché, M. Côté, 2005, Gynecologic oncology.

Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis

C. Rancourt, A. Piché, D. Lane, 2013, Journal of Ovarian Research.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Clement Adebamowo, Ritika Kundra, Steven J. M. Jones, 2018, Cell reports.

Gene therapy for HIV infections: Intracellular immunization.

A. Piché, Alain Piché, 1999, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers

C. Le Page, A. Mes-Masson, D. Huntsman, 2018, BMC Cancer.

Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers

C. Rancourt, A. Piché, D. Lane, 2015, BMC Cancer.

Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis

C. Rancourt, A. Piché, D. Lane, 2012, Molecular Cancer.

Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis

C. Rancourt, A. Piché, D. Lane, 2012, Journal of Ovarian Research.

The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells

C. Rancourt, A. Piché, D. Lane, 2010, Oncogene.

Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation

C. Rancourt, A. Piché, D. Lane, 2010, Oncogene.

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.

C. Rancourt, A. Piché, M. Côté, 2004, Gynecologic oncology.

Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy.

D. Curiel, C. Rancourt, M. Wang, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer

C. Rancourt, A. Piché, D. Lane, 2012 .

BAG-1 p29 protein prevents drug-induced cell death in the presence of EGF and enhances resistance to anoikis in SKOV3 human ovarian cancer cells.

C. Rancourt, A. Piché, M. Côté, 2005, Biochemical and biophysical research communications.

Acquired resistance to TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover of mature caspase-3

A. Piché, M. Côté, D. Lane, 2006, Molecular Cancer Therapeutics.

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike

Matthew S. Miller, E. Haddad, J. Richard, 2020, Cell Reports Medicine.

Profiling of cytokines in human epithelial ovarian cancer ascites.

C. Rancourt, A. Piché, D. Lane, 2012, American journal of cancer research.

Bcl-XL is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells

A. Piché, P. Dodier, 2006 .

Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors

S. Trottier, J. Singer, C. Kovacs, 2016, Scientific Reports.

Efficient gene delivery into epstein-barr virus (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy.

T. Curiel, K. Kasono, J. Xiang, 1998, Biochemical and biophysical research communications.

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

A. Piché, D. Lane, P. Bessette, 2018, Cancer Microenvironment.

CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling

C. Rancourt, A. Piché, D. Lane, 2016, Molecular Cancer.

Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories

V. Martel-Laferrière, A. Finzi, A. Piché, 2020, Journal of Clinical Microbiology.

Antiapoptotic Proteins Bcl-2 and Bcl-XL Inhibit Clostridium difficile Toxin A-Induced Cell Death in Human Epithelial Cells

C. Asselin, A. Piché, L. Fortier, 2009, Infection and Immunity.

Serum CA 125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer

A. Piché, P. Bessette, Perrine Garde-Granger, 2019 .

Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer.

A. Piché, P. Bessette, Perrine Garde-Granger, 2019, American journal of cancer research.

Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.

A. Piché, P. Dodier, 2006, Gynecologic oncology.

Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer.

G F Pierce, G P Siegal, D. Curiel, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer

C. Rancourt, A. Piché, D. Lane, 2010, Journal of ovarian research.

Functional knock-out of c-myb by an intracellular anti-c-Myb single-chain antibody.

K. Kasono, K. Moelling, G. Bilbao, 1998, Biochemical and biophysical research communications.

MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling.

C. Rancourt, A. Piché, I. Matte, 2015, American journal of cancer research.

MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis.

Maxime Pinard, C. Rancourt, A. Piché, 2011, Gynecologic oncology.

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway

A. Piché, P. Bessette, Perrine Garde-Granger, 2019, BMC cancer.

Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions

C. Rancourt, A. Piché, P. Bessette, 2016, Clinical & Experimental Metastasis.

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression

C. Rancourt, A. Piché, D. Lane, 2014, BMC Cancer.

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells

C. Rancourt, A. Piché, M. Boivin, 2011, British Journal of Cancer.

Pathobiological role of MUC16 mucin (CA125) in ovarian cancer: Much more than a tumor biomarker

A. Piché, 2016 .

MUC16 mucin (CA125) attenuates TRAIL-induced apoptosis by decreasing TRAIL receptor R2 expression and increasing c-FLIP expression

C. Rancourt, A. Piché, D. Lane, 2014, BMC Cancer.

Biological Significance of Apoptosis in Ovarian Cancer: TRAIL Therapeutic Targeting

C. Rancourt, A. Piché, D. Lane, 2013 .

Role of malignant ascites on human mesothelial cells and their gene expression profiles

D. Bachvarov, C. Rancourt, A. Piché, 2014, BMC Cancer.

Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression: Impact and significance

A. Piché, 2018, World journal of clinical oncology.

Role of malignant ascites on human mesothelial cells and their gene expression profiles

D. Bachvarov, C. Rancourt, A. Piché, 2014, BMC Cancer.

The Biobanque québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories

A. Montpetit, A. Mes-Masson, F. Maltais, 2021, PloS one.

The cost-effectiveness of highly active antiretroviral therapy, Canada 1991–2001

E. Beck, A. Piché, C. Hankins, 2004, AIDS.

Trajectories of health-related quality of life and their predictors in adult COVID-19 survivors: A longitudinal analysis of the Biobanque Québécoise de la COVID-19 (BQC-19)

H. Corriveau, G. Bravo, D. Kairy, 2023, Quality of Life Research.

Gene therapy strategies for AIDS-related malignancies

K. Kasono, D. Curiel, A. Piché, 1997, Gene Therapy.

Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway

A. Piché, P. Bessette, Perrine Garde-Granger, 2019, BMC Cancer.

SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition

Jean-François Lucier, L. Premkumar, Y. Durocher, 2023, bioRxiv.